362 related articles for article (PubMed ID: 19740374)
1. Discrimination between the main activating and inhibitory killer cell immunoglobulin-like receptor positive natural killer cell subsets using newly characterized monoclonal antibodies.
David G; Morvan M; Gagne K; Kerdudou N; Willem C; Devys A; Bonneville M; Folléa G; Bignon JD; Retière C
Immunology; 2009 Oct; 128(2):172-84. PubMed ID: 19740374
[TBL] [Abstract][Full Text] [Related]
2. Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 SPECIFICITY of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation.
David G; Djaoud Z; Willem C; Legrand N; Rettman P; Gagne K; Cesbron A; Retière C
J Immunol; 2013 Nov; 191(9):4778-88. PubMed ID: 24078689
[TBL] [Abstract][Full Text] [Related]
3. Novel Approach to Cell Surface Discrimination Between KIR2DL1 Subtypes and KIR2DS1 Identifies Hierarchies in NK Repertoire, Education, and Tolerance.
Le Luduec JB; Boudreau JE; Freiberg JC; Hsu KC
Front Immunol; 2019; 10():734. PubMed ID: 31024561
[TBL] [Abstract][Full Text] [Related]
4. Polymorphic HLA-C Receptors Balance the Functional Characteristics of KIR Haplotypes.
Hilton HG; Guethlein LA; Goyos A; Nemat-Gorgani N; Bushnell DA; Norman PJ; Parham P
J Immunol; 2015 Oct; 195(7):3160-70. PubMed ID: 26311903
[TBL] [Abstract][Full Text] [Related]
5. Characterization of KIR
Meazza R; Falco M; Canevali P; Loiacono F; Colomar-Carando N; Muntasell A; Rea A; Mingari MC; Locatelli F; Moretta L; Lopez-Botet M; Pende D
HLA; 2022 Aug; 100(2):119-132. PubMed ID: 35439359
[TBL] [Abstract][Full Text] [Related]
6. [Killer immunoglobulin-like receptor gene genotype and expression pattern in NK-92MI and K562 cells].
Dou LP; DA WM; Liu JH; Sun JF; Zhao Y; Wang QS; Gao CJ; Yu L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Sep; 25(9):767-9. PubMed ID: 19737456
[TBL] [Abstract][Full Text] [Related]
7. KIR2DL3 and KIR2DL1 show similar impact on licensing of human NK cells.
Sim MJ; Stowell J; Sergeant R; Altmann DM; Long EO; Boyton RJ
Eur J Immunol; 2016 Jan; 46(1):185-91. PubMed ID: 26467237
[TBL] [Abstract][Full Text] [Related]
8. Influence of HLA-C environment on the spontaneous clearance of hepatitis C in European HIV-HCV co-infected individuals.
Legrand N; David G; Rodallec A; Gaultier A; Salmon D; Cesbron A; Wittkop L; Raffi F; Gendzekhadze K; Retière C; Allavena C; Gagne K
Clin Exp Immunol; 2021 Apr; 204(1):107-124. PubMed ID: 33314121
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies with various reactivity to p58 killer inhibitory receptors.
Shin JS; Shin EC; Kim J; Choi IH; Park JH; Kim SJ
Hybridoma; 1999 Dec; 18(6):521-7. PubMed ID: 10626681
[TBL] [Abstract][Full Text] [Related]
10. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.
Romagné F; André P; Spee P; Zahn S; Anfossi N; Gauthier L; Capanni M; Ruggeri L; Benson DM; Blaser BW; Della Chiesa M; Moretta A; Vivier E; Caligiuri MA; Velardi A; Wagtmann N
Blood; 2009 Sep; 114(13):2667-77. PubMed ID: 19553639
[TBL] [Abstract][Full Text] [Related]
11. [Killer immunoglobulin-like receptor gene genotype and expression pattern in healthy people].
Dou LP; DA WM; Huang WR; Li HH; Zhao Y; Wang QS; Gao CJ; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):132-5. PubMed ID: 20137133
[TBL] [Abstract][Full Text] [Related]
12. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
13. Biphasic response of NK cells expressing both activating and inhibitory killer Ig-like receptors.
Warren HS; Campbell AJ; Waldron JC; Lanier LL
Int Immunol; 2001 Aug; 13(8):1043-52. PubMed ID: 11470774
[TBL] [Abstract][Full Text] [Related]
14. Expression of the HLA-C2-specific activating killer-cell Ig-like receptor KIR2DS1 on NK and T cells.
Cognet C; Farnarier C; Gauthier L; Frassati C; André P; Magérus-Chatinet A; Anfossi N; Rieux-Laucat F; Vivier E; Schleinitz N
Clin Immunol; 2010 Apr; 135(1):26-32. PubMed ID: 20093094
[TBL] [Abstract][Full Text] [Related]
15. Isolation of a novel KIR2DL3-specific mAb: comparative analysis of the surface distribution and function of KIR2DL2, KIR2DL3 and KIR2DS2.
Vitale M; Carlomagno S; Falco M; Pende D; Romeo E; Rivera P; Della Chiesa M; Mavilio D; Moretta A
Int Immunol; 2004 Oct; 16(10):1459-66. PubMed ID: 15314042
[TBL] [Abstract][Full Text] [Related]
16. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells.
Moretta A; Sivori S; Vitale M; Pende D; Morelli L; Augugliaro R; Bottino C; Moretta L
J Exp Med; 1995 Sep; 182(3):875-84. PubMed ID: 7650491
[TBL] [Abstract][Full Text] [Related]
17. Resurrecting KIR2DP1: A Key Intermediate in the Evolution of Human Inhibitory NK Cell Receptors That Recognize HLA-C.
Hilton HG; Blokhuis JH; Guethlein LA; Norman PJ; Parham P
J Immunol; 2017 Mar; 198(5):1961-1973. PubMed ID: 28122963
[No Abstract] [Full Text] [Related]
18. Comparative analysis of NK cell subset distribution in normal and lymphoproliferative disease of granular lymphocyte conditions.
Pascal V; Schleinitz N; Brunet C; Ravet S; Bonnet E; Lafarge X; Touinssi M; Reviron D; Viallard JF; Moreau JF; Déchanet-Merville J; Blanco P; Harlé JR; Sampol J; Vivier E; Dignat-George F; Paul P
Eur J Immunol; 2004 Oct; 34(10):2930-40. PubMed ID: 15368309
[TBL] [Abstract][Full Text] [Related]
19. Mutation at positively selected positions in the binding site for HLA-C shows that KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3.
Hilton HG; Vago L; Older Aguilar AM; Moesta AK; Graef T; Abi-Rached L; Norman PJ; Guethlein LA; Fleischhauer K; Parham P
J Immunol; 2012 Aug; 189(3):1418-30. PubMed ID: 22772445
[TBL] [Abstract][Full Text] [Related]
20. Epitope characterization of a monoclonal antibody that selectively recognizes KIR2DL1 allotypes.
Falco M; Meazza R; Alicata C; Canevali P; Muntasell A; Bottino C; Moretta L; Pende D; Lopez-Botet M
HLA; 2022 Aug; 100(2):107-118. PubMed ID: 35411634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
